Skip to main content
. 2021 Apr 22;11(5):258. doi: 10.3390/metabo11050258

Figure 2.

Figure 2

Inhibition of fibrotic marker expression by SCFA treatment of activated pulmonary fibroblasts. (A) MRC5 cells were treated with PBS or TGF-β1 (5 ng/mL) for 12 h in the presence of C2, C3, or C4 SCFAs (10 mM). Data are expressed as means ± SEM of three independent experiments, ## p < 0.01; mock-treated cells from PBS-treated group vs. mock-treated cells from TGF-β1-treated group, * p < 0.05 and ** p < 0.01; mock-treated cells vs. C3 or C4-treated cells from each PBS or TGF-β1-treated group. (B) MRC5 cells were treated with TGF-β1 (5 ng/mL) for 48 h with the indicated amounts of C2, C3, or C4. Total RNA was prepared and subjected to RT and qPCR analysis for expression of fibrotic markers. Data are expressed as means ± SEM of three independent experiments, ### p < 0.001; mock-treated cells vs. TGF-β1-treated cells, * p < 0.05, ** p < 0.01 and *** p < 0.001; TGF-β1-treated cells vs. TGF-β1 + C2, C3 or C4-treated cells.